Lever
Lifestyle
- Regular exercise
- Adequate sleep
- Stress management
Blutwerte · Marker
IGFBP-3
Insulin-like Growth Factor Binding Protein 3 · IGF Binding Protein 3
Hormone — GH/IGF-Achse
- Einheit:
- ng/mL
IGFBP-3 quantifies the concentration of insulin-like growth factor binding protein 3 in the blood, which modulates IGF-I bioavailability.
Reference Ranges
Reference
3.4–7.1ng/mL
3.4
7.1
LowNormalHigh
Reference
Unit · ng/mLReference ranges may vary based on age, sex, and laboratory methods.
Overview
Übersicht
Insulin-like Growth Factor Binding Protein 3 (IGFBP-3) is a key component of the insulin-like growth factor (IGF) system, primarily responsible for modulating the bioavailability and activity of IGFs, particularly IGF-I. It acts by binding to IGFs in circulation and the extracellular environment, influencing cellular growth, proliferation, and differentiation. IGFBP-3 also exhibits IGF-independent effects, including antiproliferative and proapoptotic actions, which are significant in various physiological and pathological contexts. Clinically, IGFBP-3 is implicated in the pathophysiology of diseases such as cancer, diabetes, and malnutrition. Elevated levels of IGFBP-3 have been associated with increased cancer risk, particularly in premenopausal breast cancer, while lower levels may indicate poorer prognosis in conditions like oesophageal squamous cell carcinoma (ESCC). For athletes and biohackers, IGFBP-3's role in regulating IGF-I bioavailability makes it relevant for muscle growth, recovery, and overall metabolic health. Its modulation could potentially influence performance and longevity strategies. However, researchers have noted that IGFBP-3 levels can be influenced by factors such as nutritional status, insulin levels, and possibly time of day, necessitating careful consideration when interpreting results.
Klinische Bedeutung
Elevated IGFBP-3 levels may be associated with increased cancer risk, particularly in premenopausal breast cancer. Reduced levels can indicate a poorer prognosis in oesophageal squamous cell carcinoma and may correlate with reduced survival rates.
Dynamics
Trend Interpretation
Rising Values
Progressively rising IGFBP-3 levels may suggest increased IGF-I activity or potential cancer risk. Re-test in 3-6 months if levels are significantly elevated.
Falling Values
Progressively falling levels may indicate malnutrition, liver dysfunction, or chronic illness.
Re-test Interval
6 months if outside optimal range
Etiology
Causes — High & Low
Cause
Elevated Levels
- Increased IGF-I levels
- Certain cancers
- High insulin levels
- Exogenous growth hormone use
- Liver dysfunction
Cause
Low Levels
- Malnutrition
- Diabetes mellitus
- Liver disease
- Chronic illness
- Aging
Protocol
How to Optimize
Lever
Nutrition
- Balanced diet with adequate protein
- Omega-3 fatty acids
- Antioxidant-rich foods
Lever
Supplementation
- Zinc
- Vitamin D
Note:
Consult a healthcare provider before making significant lifestyle or dietary changes.
Testing Guidelines
✓Fasting Not Required
✓Not Time-Sensitive
IGFBP-3 levels can vary throughout the day; morning samples are recommended.
Testing Frequency
Annually for general health monitoring, more frequently if clinically indicated.
Interfering Factors
- Recent intense exercise
- Acute illness
- Medication use
Related Markers
Related Peptides & Hormones
Igf 1
hormoneCorrelated with
Open Research Questions
Current research suggests that the optimal reference ranges and targets for IGFBP-3 in various cancer types remain unclear, particularly regarding its role in different stages of disease. Researchers have not yet established the confounding effects of metabolic conditions on IGFBP-3 levels, nor the precise mechanisms of its IGF-independent actions. Additionally, clinical questions regarding the predictive value of IGFBP-3 in diverse cancer prognoses and its potential therapeutic applications remain unanswered.
50 Research Publications
2,867
Total Citations
25
Human/RCT
6.6
Avg. Influence
2024
Latest
Sort
Filter
01Top
#01
Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis.
Meta-AnalysisInfluence47.0
1682
This study examined the relationship between insulin-like growth factor (IGF)-I, IGF binding protein-3 (IGFBP-3), and cancer risk. Researchers found that high levels of IGF-I were linked to an increased risk of prostate and premenopausal breast cancer, while high IGFBP-3 levels were associated with a higher risk of premenopausal breast cancer. The findings suggest that both biomarkers could play a role in cancer risk assessment.
02Top
#02
Unraveling insulin-like growth factor binding protein-3 actions in human disease.
ReviewInfluence31.0
314
Researchers explored the actions of IGFBP-3 in various human diseases. They found that IGFBP-3 has biological effects independent of the IGF/IGF-I receptor axis, contributing to the pathophysiology of conditions like cancer and diabetes. The study emphasizes the importance of understanding these independent actions for clinical significance.
03Top
#03
Diet, serum insulin-like growth factor-I and IGF-binding protein-3 in European women.
HumanInfluence4.0
157
This study explored the relationship between diet and serum levels of IGF-I and IGFBP-3 in European women. Researchers observed that serum IGF-I was positively related to protein intake, while IGFBP-3 levels showed no significant correlation with dietary factors. The findings suggest that dietary habits may influence IGF-I but not IGFBP-3 levels.
04
#04
IGFBP-3/IGFBP-3 Receptor System as an Anti-Tumor and Anti-Metastatic Signaling in Cancer.
ReviewInfluence8.0
109
Researchers reviewed the anti-tumor and anti-metastatic roles of IGFBP-3 in cancer. They found that IGFBP-3 has both tumor-suppressing and tumor-promoting effects depending on various factors, emphasizing its clinical significance in cancer diagnosis and prognosis.
05
#05
Molecular regulation of insulin-like growth factor-I and its principal binding protein, IGFBP-3.
In VitroInfluence2.0
97
This research focused on the molecular regulation of IGF-I and IGFBP-3. Researchers found that IGFBP-3 levels are influenced by insulin and that its production is primarily regulated in the liver. The study highlights the importance of understanding these regulatory mechanisms in metabolic disorders.
06
#06
Elevated plasma MCP-1 concentration following traumatic brain injury as a potential "predisposition" factor associated with an increased risk for subsequent development of Alzheimer's disease.
HumanInfluence3.0
45
This study explored changes in plasma proteins, including insulin-like growth factor binding protein-3 (IGFBP-3), in individuals with traumatic brain injury (TBI). Researchers found that IGFBP-3 levels were differentially regulated in TBI cases and correlated with the severity of the injury, suggesting its potential role in TBI complications.
07
#07
Clinical assays for quantitation of insulin-like-growth-factor-1 (IGF1).
Review
44
This review focused on clinical assays for quantifying IGF-1, highlighting the importance of IGFBP-3 in its measurement. Researchers noted that IGFBP-3 can interfere with immunoassays, necessitating careful assay methodology for accurate IGF-1 quantification.
08
#08
Laboratory investigations in the diagnosis and follow-up of GH-related disorders.
Schilbach Katharina & Bidlingmaier Martin · Archives of endocrinology and metabolism · 2019
ReviewInfluence2.0
37
This review discussed laboratory investigations for diagnosing growth hormone-related disorders, emphasizing the role of IGFBP-3. Researchers highlighted the challenges in measuring IGF-I and IGFBP-3 due to biological variability and assay differences.
Key findings
- 01Researchers observed that different assay methods for measuring GH and IGF-I can yield varying results due to differences in specificity and sensitivity.
- 02They found that biological factors such as age and puberty significantly affect IGF-I levels, necessitating specific reference intervals for accurate diagnosis.
- 03The study highlighted that GH levels fluctuate due to factors like stress and exercise, complicating the interpretation of test results.
09
#09
Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer.
HumanInfluence1.0
33
Researchers evaluated the safety and tolerability of figitumumab combined with carboplatin and paclitaxel in Japanese patients with advanced non-small cell lung cancer. They found that serum levels of IGF-1 and IGFBP-3 increased following treatment, although a clear dose-dependent relationship was not established.
10
#10
Semaphorin 6A Attenuates the Migration Capability of Lung Cancer Cells via the NRF2/HMOX1 Axis.
In Vitro
32
Clinical Trials (1)
1
Total Trials
16
Total Enrolled
IGF-I and Free Fatty Acids Isn Glucose Metabolism in Acromegaly
NCT02084095COMPLETED
Sponsor
Carol Davila University of Medicine and Pharmacy
Enrollment
16
Started
2014
Primary outcome
The correlation coefficient between IGFBP-3 and insulin resistance assessed using Bergman model is non-inferior to the correlation coefficient between IGF-I and insulin resistance
Acromegaly
Publication Trend
Research publications about IGFBP-3 over time
9totalTrack your bloodwork in PepStack
Log lab results, track trends and optimize your biomarkers over time.
Legal Disclaimer
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer